DCTH vs. ALUR, STIM, TELA, KRMD, BLUA, BWAY, MGRM, CLPT, QIPT, and OBIO
Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include Allurion Technologies (ALUR), Neuronetics (STIM), TELA Bio (TELA), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Monogram Orthopaedics (MGRM), ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), and Orchestra BioMed (OBIO). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Delcath Systems received 18 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 100.00% of users gave Allurion Technologies an outperform vote while only 20.00% of users gave Delcath Systems an outperform vote.
Allurion Technologies has a net margin of 0.00% compared to Delcath Systems' net margin of -2,308.86%. Allurion Technologies' return on equity of 0.00% beat Delcath Systems' return on equity.
Delcath Systems has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500.
Delcath Systems currently has a consensus target price of $18.50, indicating a potential upside of 251.71%. Allurion Technologies has a consensus target price of $5.00, indicating a potential upside of 168.82%. Given Delcath Systems' higher probable upside, equities analysts clearly believe Delcath Systems is more favorable than Allurion Technologies.
In the previous week, Delcath Systems had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for Delcath Systems and 1 mentions for Allurion Technologies. Delcath Systems' average media sentiment score of 0.55 beat Allurion Technologies' score of -0.18 indicating that Delcath Systems is being referred to more favorably in the media.
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 17.9% of Delcath Systems shares are held by company insiders. Comparatively, 20.0% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Delcath Systems has higher earnings, but lower revenue than Allurion Technologies.
Summary
Delcath Systems beats Allurion Technologies on 9 of the 15 factors compared between the two stocks.
Get Delcath Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Delcath Systems Competitors List
Related Companies and Tools
